Form 4: OptimizeRx CEO William Febbo Receives 60,000 Restricted Stock Units

OptimizeRx CEO William Febbo was granted 60,000 restricted stock units on April 15, 2024, which will vest in three equal annual installments starting April 15, 2025.

Summary

• William J Febbo, CEO of OptimizeRx Corp, received 60,000 restricted stock units on April 15, 2024.
• These restricted stock units represent a contingent right to receive shares of OptimizeRx common stock.
• The units will vest in three equal annual installments, beginning on April 15, 2025.
• Following the transaction, Febbo beneficially owns 538,144 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of restricted stock units is a standard practice and indicates confidence in the company's future performance. It aligns management's interests with shareholders.

Positives

• The grant of restricted stock units aligns the CEO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The restricted stock units will vest over the next three years, incentivizing the CEO to drive long-term value for the company.

Industry Context

Grants of restricted stock units are a common form of executive compensation in the technology and healthcare industries, aligning management incentives with shareholder value creation.

Stakeholder Impact

• Shareholders: The grant of restricted stock units aligns the CEO's interests with those of the shareholders, potentially leading to increased shareholder value.
• Employees: The grant could boost employee morale by demonstrating confidence in the company's leadership and future prospects.

Key Dates